Cortisol and response to dexamethasone as predictors of withdrawal distress and abstinence success in smokers.

Background: Glucocorticoids have been linked to self-administration of a wide range of drugs in animals and are increased endogenously by chronic nicotine intake. Corticosteroids have also been shown to regulate nicotine receptor sensitivity and to be involved in behavioral sensitization to nicotine.

Methods: Cortisol levels and cortisol suppression in response to dexamethasone were measured in a sample of smokers participating in a smoking cessation treatment trial.

Clinical effects of naltrexone on autistic behavior.

Eight young adults who were diagnosed with autism were given the opiate antagonist naltrexone to control self-injurious behavior and maladaptive idiosyncratic mannerisms. The drug and placebo were administered in a double-blind crossover design over 17 weeks. Although one subject appeared to have partial decreases in maladaptive behaviors associated with naltrexone use, the drugs, as administered in this study, did not reduce the self-injurious and other maladaptive behaviors of the subjects.

Responses of female rhesus macaques to an environmental enrichment apparatus.

Environmental enrichment devices are a potential way to enhance psychological well-being in laboratory animals. The effects of such devices need to be systematically evaluated before they are recommended for widespread use. The purpose of this research was to monitor the behavioural and physiological responses of adult female rhesus macaques to a simple enrichment device.

Lifetime antipsychotic-drug exposure, dyskinesia and related movement disorders in the developmentally disabled.

The relationship between dyskinesia and related movement disorders was examined as a function of cumulative exposure to antipsychotic drugs (APD). Lifetime drug-exposure histories were obtained for 162 developmentally disabled (DD) persons; drug-exposed groups were compared to nondrug-exposed groups. There were no statistically significant relationships between dyskinesia and the amount of lifetime APD exposure, nor between dyskinesia and the number of long-term APDs, mean exposure, peak exposure, recency of exposure, duration of exposure, changes in medication levels, number of drug interruptions, age, gender, cerebral palsy, epilepsy, or IQ.